Shanghai Circode Biomed is initiating clinical trials for HM-2002, a circRNA-based therapeutic for ischemic heart disease with regulatory clearances in China and the US. Separately, Renasant Bio launched with $54.5 million seed funding to develop disease-modifying treatments for autosomal dominant polycystic kidney disease (ADPKD), advancing a corrector program and first-in-class potentiator efforts. These initiatives underscore innovation in RNA therapeutics and rare disease pipelines.